Literature DB >> 27112676

Detection methods for neural autoantibodies.

Patrick Waters1, Philippa Pettingill2, Bethan Lang3.   

Abstract

Antibodies are part of the adaptive immune response that provides protection against microorganisms. In rare instances individuals can develop antibodies that bind to normal central nervous system structures. These antibodies have been classified into two groups depending on the subcellular location of their target antigens. Biomarker antibodies bind to cytosolic or nuclear targets. They do not impact on the normal function of the cell, but are most often paraneoplastic biomarkers that may suggest screening for different cancers. The second, more recently discovered group of antibodies recognize the three-dimensional structure of native proteins that are accessible on the cell surface. Understanding of this important difference is reflected in the nature of assays used to detect antibodies in these two groups. Western blots and, more recently, line blots, both of which use linear, denatured targets, are used to detect antibodies to intracellular targets. Newer assays have been developed that maintain the native structure of protein targets to permit detection of antibodies that recognize extracellular targets. In this chapter we describe the methods used to detect both antibody types, and discuss assay cut-offs, sample handling, and which biologic fluid to test.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CNS; ELISA; IgG; antibody; assay; cell-based assay; flow cytometry; immunoglobulin; immunohistochemistry; immunoprecipitation

Mesh:

Substances:

Year:  2016        PMID: 27112676     DOI: 10.1016/B978-0-444-63432-0.00009-8

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  6 in total

1.  Practice Current: When do you suspect autoimmune encephalitis and what is the role of antibody testing?

Authors:  Aravind Ganesh; Sarah F Wesley
Journal:  Neurol Clin Pract       Date:  2018-02

Review 2.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

Review 3.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

4.  Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.

Authors:  Alberto Vogrig; Marine Fouret; Bastien Joubert; Géraldine Picard; Véronique Rogemond; Anne-Laurie Pinto; Sergio Muñiz-Castrillo; Maxime Roger; Judith Raimbourg; Charles Dayen; Laurianne Grignou; Maud Pallix-Guyot; Julien Lannoy; François Ducray; Virginie Desestret; Dimitri Psimaras; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-07

5.  Optimal encephalitis/meningitis roadmap via precise diagnosis and treatment (IMPROVE): a study protocol for a randomized controlled trial.

Authors:  Yi Zhang; Haocheng Zhang; Bo Deng; Ke Lin; Lei Jin; Xiaoni Liu; Yanlin Zhang; Xiaohua Chen; Yanliang Zhang; Shengjia Lu; Heqing Huang; Qiujing Wang; Tingting Feng; Weifeng Zhao; Qun Xue; Renfang Chen; Jingbo Zhang; Xiaoyan Qian; Lanlan Chen; Jingwen Ai; Xiangjun Chen; Wenhong Zhang
Journal:  BMC Infect Dis       Date:  2022-01-08       Impact factor: 3.090

6.  Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies.

Authors:  Claire Simard; Alberto Vogrig; Bastien Joubert; Sergio Muñiz-Castrillo; Géraldine Picard; Véronique Rogemond; François Ducray; Giulia Berzero; Dimitri Psimaras; Jean-Christophe Antoine; Virginie Desestret; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.